Back

A randomized, pharmacodynamic comparison of low dose ticagrelor (60mg bid) to low dose prasugrel (5mg od) in patients with prior myocardial infarction: the ALTIC-2 study

31 August 2019 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster Session 3 - Antiplatelet therapy Antiplatelet Drugs ESC Premium Access ESC Congress 2019

About the speaker

Photo
Doctor Ioannis Lianos

Guy's and St Thomas' NHS Trust Hospitals, London (United Kingdom of Great Britain & Northern Ireland)

4 More presentations in this session

Presentation thumbnail
Triple vs. double antithrombotic therapy in patients needing oral anticoagulation undergoing percutaneous coronary intervention: a meta-analysis
Doctor D. Errigo (Turin, IT)
Abstract Slides
Presentation thumbnail
Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischaemic risk compared with 75-100 mg aspirin daily in coronary artery disease patients
Doctor J. Li (Beijing, CN)
Abstract
Presentation thumbnail
Bleedings during antithrombotic therapy: a blessing in disguise
Doctor D. Cosmi (Perugia, IT)
Abstract Slides
Presentation thumbnail
Efficacy and safety of oral anticoagulant versus antiplatelet therapy for secondary prevention of cardiovascular disease in patients without atrial fibrillation
Assistant Professor F. Ricci (Chieti, IT)
Abstract

Access the full session

Session thumbnail
Poster Session 3 - Antiplatelet therapy

The Event

Event poster

ESC Congress 2019

31 August - 4 September 2019
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Parenteral antiplatelet agents: when should they be used?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources